ForbesCelgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack CancerForbesThat cash is a launch pad for a business that aims to be a successor to the hottest biotech companies around today: CAR-T companies like Juno Therapeu… Continue reading
CNET |
Celularity turns to placenta stem cells to try to extend life
CNET Humans have always been obsessed with stalling death. It’s something countless characters and historical figures have sought, from Gilgamesh to Juan Ponce de Leon. The fascination has endured in the modern world too, with the US longevity sector worth … Peter Diamandis Is the Latest Tech Futurist Betting on Stem CellsWIRED A startup that wants to use stem cells to keep us living longer just raised $250 millionBusiness Insider Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack CancerForbes FierceBiotech all 8 news articles » |
|
Merck KGaA, Pfizer’s immunotherapy fails in lung cancer trial
Reuters FRANKFURT (Reuters) – Merck KGaA and Pfizer’s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The results revealed on Thursday mark another setback … |
News-Medical.net |
New guidelines offer recommendations for assessment, management of immunotherapy side effects
News-Medical.net Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body’s immune system to attack cancer, these treatments can … NCCN teams up with ASCO to provide guidelines for use of new cancer-fighting drugsPhiladelphia Business Journal Global Cancer Immunotherapy Market Performance by 2026: Hoffman La Roche, LLC, Bayer AG, Novartis, Merck …Herald Of Technology – Market News (press release) |
The Philadelphia Tribune |
Can gene therapy be harnessed to fight the AIDS virus?
The Philadelphia Tribune “Gene therapy techniques have advanced greatly,” said Dr. Otto Yang of the UCLA AIDS Institute, one place working on this. “A lot of people are thinking it’s the right time to go back.” They include Dr. Anthony Fauci, director of the National Institute … |